首页

Zhaoke Ophthalmology Announces 2023 Annual Results:First Annual Sales Revenue Recognized Solid Progress Made in Key Clinical Programs

2024-03-27

2587

Zhaoke Ophthalmology Expands Commercialization Activities With Distribution Agreement For Bimatoprost Timolol in Malaysia

2024-03-05

1975

Zhaoke Ophthalmology Partners With Kwangdong Pharmaceutical Co., Ltd. To Commercialize BRIMOCHOL PF In South Korea

2024-01-29

2353

Zhaoke Ophthalmology’s IND Applications for Clinical Trial of BRIMOCHOL PF and CARBACHOL PF for the Treatment of Presbyopia Approved by NMPA

2024-01-24

2372

[Podcast] Special Feature on NVK002 for Treatment of Myopia in Children (II)

2023-10-26

2248

首页 1 2 3 4 5 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat